Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Adult
Aged
Aged, 80 and over
Cohort Studies
Female
Fusion Proteins, bcr-abl
/ genetics
Gene Expression Regulation, Neoplastic
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ drug therapy
Male
Middle Aged
Neoplasm, Residual
/ diagnosis
Polymerase Chain Reaction
/ methods
Protein Kinase Inhibitors
/ therapeutic use
Sensitivity and Specificity
Treatment Outcome
Young Adult
chronic myeloid leukemia
digital PCR (dPCR)
minimal residual disease (MRD) monitoring
treatment-free remission (TFR)
tyrosine kinase inhibitors (TKI) discontinuation
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
26
10
2018
revised:
20
02
2019
accepted:
20
02
2019
pubmed:
6
4
2019
medline:
11
6
2020
entrez:
6
4
2019
Statut:
ppublish
Résumé
Treatment-free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation in patients with deep molecular response (DMR) is a paramount goal in the current chronic myeloid leukemia (CML) therapeutic strategy. The best DMR level by real-time quantitative PCR (RT-qPCR) for TKI discontinuation is still a matter of debate. To compare the accuracy of digital PCR (dPCR) and RT-qPCR for BCR-ABL1 transcript levels detection, 142 CML patients were monitored for a median time of 24 months. Digital PCR detected BCR-ABL1 transcripts in the RT-qPCR undetectable cases. The dPCR analysis of the samples, grouped by the MR classes, revealed a significant difference between MR
Identifiants
pubmed: 30950237
doi: 10.1002/cam4.2087
pmc: PMC6536984
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Fusion Proteins, bcr-abl
EC 2.7.10.2
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2041-2055Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Blood. 2017 Feb 16;129(7):846-854
pubmed: 27932374
Br J Haematol. 2018 Jan;180(1):24-32
pubmed: 29048128
Lancet. 2007 Jul 28;370(9584):342-50
pubmed: 17662883
Cancer. 2017 Nov 15;123(22):4403-4410
pubmed: 28743166
J Clin Oncol. 2017 Jan 20;35(3):298-305
pubmed: 28095277
Leukemia. 2003 Dec;17(12):2318-57
pubmed: 14562125
Nat Rev Clin Oncol. 2017 Apr;14(4):201-202
pubmed: 28169304
J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596
pubmed: 28364360
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
Leukemia. 2015 May;29(5):999-1003
pubmed: 25652737
Clin Chem. 2015 Jan;61(1):79-88
pubmed: 25338683
Blood. 2013 Jul 25;122(4):515-22
pubmed: 23704092
Ther Adv Hematol. 2016 Oct;7(5):237-251
pubmed: 27695615
Leukemia. 2016 Aug;30(8):1638-47
pubmed: 27133824
Blood. 2016 Jul 7;128(1):17-23
pubmed: 27013442
Oncologist. 2016 May;21(5):626-33
pubmed: 27032870
Br J Haematol. 2014 Jul;166(1):3-11
pubmed: 24754670
Cancer Med. 2016 Sep;5(9):2398-411
pubmed: 27367039
Blood. 2008 Oct 15;112(8):3330-8
pubmed: 18684859
Int J Hematol. 2018 Feb;107(2):185-193
pubmed: 28929332
Ann Oncol. 2017 Jul 1;28(suppl_4):iv41-iv51
pubmed: 28881915
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):156-163
pubmed: 27913475
Biomol Detect Quantif. 2017 Feb 14;11:4-20
pubmed: 28331814
J Clin Pathol. 2016 Sep;69(9):817-21
pubmed: 26837312
Lancet Haematol. 2015 May;2(5):e186-93
pubmed: 26688093
Lancet Oncol. 2010 Nov;11(11):1029-35
pubmed: 20965785
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Cancer Med. 2019 May;8(5):2041-2055
pubmed: 30950237
Clin Chem. 2017 Feb;63(2):525-531
pubmed: 27979961
Leukemia. 2010 Oct;24(10):1719-24
pubmed: 20811403
Leukemia. 2016 Aug;30(8):1648-71
pubmed: 27121688
Haematologica. 2018 Nov;103(11):1835-1842
pubmed: 29976734
Cancer. 2018 Jul 15;124(14):2956-2963
pubmed: 29723417
Biosens Bioelectron. 2017 Apr 15;90:459-474
pubmed: 27818047
Lancet Oncol. 2018 Jun;19(6):747-757
pubmed: 29735299
Blood. 2012 Mar 1;119(9):1981-7
pubmed: 22228624